ATC groups

Anatomicko-terapeuticko-chemické skupiny jsou definovány Světovou zdravotnickou organizací, viz www.whocc.no.

± A: ALIMENTARY TRACT AND METABOLISM

± B: BLOOD AND BLOOD FORMING ORGANS

± C: CARDIOVASCULAR SYSTEM

± D: DERMATOLOGICALS

± G: GENITO URINARY SYSTEM AND SEX HORMONES

± H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

± J: ANTIINFECTIVES FOR SYSTEMIC USE

± L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

± L01: ANTINEOPLASTIC AGENTS

± L02: ENDOCRINE THERAPY

± L03: IMMUNOSTIMULANTS

± L04: IMMUNOSUPPRESSANTS

± L04A: IMMUNOSUPPRESSANTS

± L04AA: SELECTIVE IMMUNOSUPPRESSANTS

L04AA02: MUROMONAB-CD3

L04AA03: ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)

L04AA04: ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)

L04AA06: MYCOPHENOLIC ACID

L04AA10: SIROLIMUS

L04AA13: LEFLUNOMIDE

L04AA15: ALEFACEPT

L04AA18: EVEROLIMUS

L04AA19: GUSPERIMUS

L04AA21: EFALIZUMAB

L04AA22: ABETIMUS

L04AA23: NATALIZUMAB

L04AA24: ABATACEPT

L04AA25: ECULIZUMAB

L04AA26: BELIMUMAB

L04AA27: FINGOLIMOD

L04AA28: BELATACEPT

L04AA29: TOFACITINIB

L04AA31: TERIFLUNOMIDE

L04AA32: APREMILAST

L04AA33: VEDOLIZUMAB

L04AA34: ALEMTUZUMAB

L04AA35: BEGELOMAB

L04AA36: OCRELIZUMAB

L04AA37: BARICITINIB

L04AA38: OZANIMOD

L04AA39: EMAPALUMAB

L04AA40: CLADRIBINE

L04AA41: IMLIFIDASE

L04AA42: SIPONIMOD

L04AA43: RAVULIZUMAB

L04AA44: UPADACITINIB

L04AA45: FILGOTINIB

L04AA46: ITACITINIB

L04AA47: INEBILIZUMAB

L04AA48: BELUMOSUDIL

L04AA49: PEFICITINIB

L04AA50: PONESIMOD

L04AA51: ANIFROLUMAB

L04AA52: OFATUMUMAB

L04AA53: TEPROTUMUMAB

L04AA54: PEGCETACOPLAN

L04AA55: SUTIMLIMAB

L04AA56: DEUCRAVACITINIB

± L04AB: TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS

± L04AC: INTERLEUKIN INHIBITORS

± L04AD: CALCINEURIN INHIBITORS

± L04AX: OTHER IMMUNOSUPPRESSANTS

± M: MUSCULO-SKELETAL SYSTEM

± N: NERVOUS SYSTEM

± P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

± R: RESPIRATORY SYSTEM

± S: SENSORY ORGANS

± V: VARIOUS